Abstracts tagged "axial spondyloarthritis"

Abstract Number: 330 • 2018 ACR/ARHP Annual Meeting
The IMPACT of a Referral Algorithm for Axial Spondyloarthritis: Four Month Follow-up in Patient Reported Outcomes
Maha Jamal¹, Amber Korver², Martijn Kuijper³, Deirisa Lopes Barreto¹, Frank van den Hoogen⁴, Cathelijne W. Y. Appels⁵, Anneke Spoorenberg⁶, Bart Koes⁷, Lonneke van Hoeven⁸, JMW Hazes⁹ and Angelique EAM Weel³, ¹Maasstad Hospital, Rotterdam, Netherlands, ²Erasmuc Medical Center, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Radboud Medical center, Nijmegen, Netherlands, ⁵Rheumatology, Amphia Hospital, Breda, Netherlands, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Erasmuc Medical center, Rotterdam, Netherlands, ⁸Erasmus Medical center, Rotterdam, Netherlands, ⁹Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: A substantial amount of patients with chronic low back pain (CLBP) have axial spondyloarthritis (axSpA), but early recognition of these patients is difficult for…
Abstract Number: 1621 • 2018 ACR/ARHP Annual Meeting
Higher Serum Uric Acid Levels Protect Against Osteoporosis in Patients with Axial Spondyloarthropathy
Gillian Fitzgerald^1,2, Tochukwu Anachebe³, Ronan Mullan⁴, David Kane⁵, Kevin McCarroll⁶ and Finbar O' Shea², ¹School of Medicine, Trinity College Dublin, Dublin 2, Ireland, ²Rheumatology, St. James's Hospital, Dublin 8, Ireland, ³Department of Rheumatology, St. James's Hospital, Dublin 8, Ireland, ⁴Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ⁵Department of Rheumatology, Tallaght Hospital, Dublin 24, Ireland, ⁶Department of Medicine for the Elderly, St. James's Hospital, Dublin 8, Ireland
Background/Purpose: High serum urate (SUA) is a risk factor for metabolic disease, including hypertension and coronary artery disease. However, SUA has an antioxidant effect and…
Abstract Number: 2601 • 2018 ACR/ARHP Annual Meeting
Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis
Hong-Ki Min¹, Hyonjoung Cho² and Sung-Hwan Park³, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Armed Forces Capital hospital, Armed Forces Medical Command, Seongnam, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The purpose of the present study was to examine the therapeutic effect of NSAIDs on active inflammatory lesions (bone marrow oedema [BMO]) in the…
Abstract Number: 1513 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Atul A. Deodhar¹, Theresa Hunter², David Sandoval Calderon³, Steve Lobosco⁴, Rachel Moon⁴ and Gary Milligan⁵, ¹Oregon Health & Science University, Portland, OR, ²Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: Timely identification of nr-axSpA may lead to earlier intervention to reduce symptoms, improve function, and reduce disease burden. The purpose of this study was…
Abstract Number: 1515 • 2017 ACR/ARHP Annual Meeting
Improvements in Enthesitis Scores with Certolizumab Pegol Treatment in Males and Females with Active Axial Spondyloarthritis Are Maintained to Week 204
Maxime Dougados¹, Philip J Mease², Joachim Sieper³, Peter C. Taylor⁴, Natasha de Peyrecave⁵, Tommi Nurminen⁶ and Jürgen Braun⁷, ¹Rheumatology Department, Paris-Descartes University and Cochin Hospital, Paris, France, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Charité University Hospital, Berlin, Germany, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA), characterized by spinal inflammation, is also associated with extra-spinal manifestations including inflammation of the entheses (enthesitis). Enthesitis is equally prevalent throughout…
Abstract Number: 1566 • 2017 ACR/ARHP Annual Meeting
Elevated IL-1 Expression Levels in Mesenchymal Stem Cells Derived from Spondyloarthitis Patients Might be Linked to Increased Osteoblast Mineralization
Gerlinde Layh-Schmitt¹, Breanna Nguyen¹, Emily Lazowick¹, Stephen R. Brooks² and Robert Colbert¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS/NIH, Biodata Mining & Discovery, Bethesda, MD
Background/Purpose: Axial spondyloarthritis (AxSpA) is an immune–mediated inflammatory disease involving the spine and sacroiliac joint. AxSpA is characterized by vertebral trabecular bone loss and progressive…
Abstract Number: 1573 • 2017 ACR/ARHP Annual Meeting
In Vivo Phosphorylation of p38 in Monocytes Is Enhanced in Patients with Axial Spondyloarthritis (axSpA) at the Time of Diagnosis
Antti Kuuliala^1,2, Krista Kuuliala^1,3, Riitta Koivuniemi^2,4, Mari Hämäläinen⁵, Eeva Moilanen⁶, Hannu Kautiainen⁷, Heikki Repo^1,3 and Marjatta Leirisalo-Repo^2,4, ¹Bacteriology and Immunology, University of Helsinki, Helsinki, Finland, ²Rheumatology, Helsinki University Hospital, Helsinki, Finland, ³Helsinki University Hospital, Helsinki, Finland, ⁴Rheumatology, University of Helsinki, Helsinki, Finland, ⁵The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, ⁶The Immunopharmacology Research Group, Faculty of Medicine and Life Sciences, University of Tampere and Tampere University Hospital, Tampere, Finland, Tampere, Finland, ⁷Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Host response to microbes is considered to contribute to the pathogenesis to axSpA and other HLA-B27 associated diseases. The p38 MAP kinase pathway plays…
Abstract Number: 1787 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis
Robert B.M. Landewé¹, Joachim Sieper², Philip J Mease³, Robert D Inman⁴, Xin Wang⁵, Mei Li⁵, Aileen L. Pangan⁵ and Jaclyn K. Anderson⁵, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Department of Immunology, University of Toronto, Toronto, ON, Canada, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: It is not known whether TNF blockers can be stopped in non-radiographic (nr-axSpA) patients who are in remission. In ABILITY-1, adalimumab (ADA) significantly improved…
Abstract Number: 1831 • 2017 ACR/ARHP Annual Meeting
A Positive MRI of the Sacroiliac Joints Is Not Specific for Axial Spondyloarthritis but Frequently Occurs in Healthy Individuals
Janneke de Winter¹, Manouk de Hooge², Marleen van de Sande¹, Lonneke van Hoeven³, Jet de Jong¹, Anoek de Koning², Inger Jorid Berg⁴, Roberta Ramonda⁵, Dominique Baeten^1,6, Désirée van der Heijde⁷, Angelique Weel⁸ and Robert B.M. Landewé⁹, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁶UCB Pharma, Slough, United Kingdom, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁹Amsterdam Rheumatology & Immunology Center, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Inflammation shown on MRI of the sacroiliac joint (MRI-SI) is prevalent in axSpA (±30%) but the specificity is not well known, hence we compared…
Abstract Number: 1877 • 2017 ACR/ARHP Annual Meeting
The Performance of MRI Using the 3D Volumetric Interpolated Breath-Hold Sequence (VIBE) Technique to Detect Structural Changes in Patients with Early Axial Spondyloarthritis in Comparison to Conventional Radiography and Computed Tomography
Xenofon Baraliakos¹, Florian Hoffmann¹, Xiaohu Deng², Yanyan Wang³, Feng Huang⁴ and Jürgen Braun⁵, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Chinese PLA General Hospital, Chinese PLA General Hospital, Beijing, China, ³Rheumatology, Chinese PLA General Hospital, Beijing, China, ⁴Chinese PLA General Hospital, Beijing, China, ⁵Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, Bielefeld, Germany
Background/Purpose: Magnetic resonance imaging (MRI) is the gold standard for detection of inflammation in the sacroiliac joints (SIJ) of patients (pts) with axial spondyloarthritis (axSpA),…
Abstract Number: 2438 • 2017 ACR/ARHP Annual Meeting
Open Label Transitioning from Originator Etanercept to Biosimilar SB4 Compared to Continuing Treatment with Originator Etanercept in a Historical Cohort in Rheumatic Diseases in Daily Practice
L. Tweehuysen¹, V.J.B. Huiskes², B.J.F. Van den Bemt (PharmD, PhD)³, S. Teerenstra⁴, F.H.J. van den Hoogen⁵, C.H.M. van den Ende⁵ and A.A. Den Broeder⁵, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ³Pharmacy, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands, ⁴Biostatistics, Radboudumc, Nijmegen, Netherlands, ⁵Rheumatology, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands
Background/Purpose: Blinded transitioning from originator infliximab (INX) to biosimilar CT-P13 was not inferior to continuing INX treatment.1 Open label mandatory transitioning resulted in a slightly…
Abstract Number: 2500 • 2017 ACR/ARHP Annual Meeting
Are Work Outcomes Improved in Axial Spondyloarthritis (axSpA) Patients with Biologic Therapy? Results from the British Society for Rheumatology Register
Gary J. Macfarlane, Gareth T. Jones and Joanna Shim, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: Patients with axial spondyloarthritis (axSpA) identify the ability to stay at work as a priority. Biologic therapy improves disease activity and quality of life…
Abstract Number: 2501 • 2017 ACR/ARHP Annual Meeting
Potential Differences in Axial Spondyloarthritis Disease Activity Categorization Using Different Minimum Values for High-Sensitivity CRP in Ankylosing Spondylitis Disease Activity Score Calculation and Different Definitions of Disease Flare
Robert B.M. Landewé¹, Joachim Sieper², Uta Kiltz³, Xin Wang⁴, Mei Li⁴ and Jaclyn K. Anderson⁴, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: It has been recommended that the lower limit of high-sensitivity CRP (hsCRP) be restricted to 2 in the Ankylosing Spondylitis Disease Activity Score (ASDAS)…
Abstract Number: 581 • 2017 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Early Axial Spondyloarthritis: Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Janneke de Winter¹, Marleen van de Sande¹, Niklas Thomas Baerlecken², Inger Berg³, Roberta Ramonda⁴, Désirée van der Heijde⁵, Floris van Gaalen⁶, Torsten Witte⁷ and Dominique Baeten^1,8, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Private Practice, Cologne, Germany, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ⁸UCB Pharma, Slough, United Kingdom
Background/Purpose: Anti-CD74 IgG antibodies are reported to be elevated in serum of patients with axial spondyloarthritis (axSpA). This study aimed to assess the diagnostic value…
Abstract Number: 2504 • 2017 ACR/ARHP Annual Meeting
The Validation of Istanbul Back Disability Index (IBDI) in Axial Spondyloarthritis Patients
Tuncay Duruoz, Hatice Sule Baklacioglu, Sevtap Acer Kasman and Didem Erdem, PMR Department, Rheumatology Division, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: The IBDI was developed to assess the disability in patients with mechanical low back pain (1) which contains the 18 daily activities questions. The…

« Previous Page
1
…
8
9
10
11
12
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].